Posted by Michael Wonder on 12 Apr 2022
Aeglea BioTherapeutics submits BLA to FDA for pegzilarginase for the treatment of arginase 1 deficiency
12 April 2022 - European marketing application on track for submission this year.
Aeglea BioTherapeutics today announced that it has submitted a biologics license application to the U.S. FDA for pegzilarginase for the treatment of arginase 1 Ddeficiency.
Aeglea requested FDA priority review at the time of the submission.
